COR vs MCK
COR: Cencora is a critical link in the global healthcare supply chain, providing pharmaceutical distribution, commercialization services, and specialty drug support to ensure patients have access to life-saving medications. MCK: A global leader in pharmaceutical distribution and healthcare technology services, connecting biopharma, providers, and patients to improve care outcomes.
Side-by-side fundamentals
| Metric | COR | MCK | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $321.35 | $930.25 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $61.3B | $108.5B | |
| P/E as of 2026-10-08 | 23.89 | 24.91 | COR lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | n/a | 1.63 | |
| Net margin | +0.5% | +1.2% | MCK higher |
| Gross margin | +3.6% | +3.6% | MCK higher |
| Operating margin | +0.8% | +1.5% | MCK higher |
| ROE FY2025, SEC XBRL | +103.1% | n/a | |
| ROA | +2.0% | +5.8% | MCK higher |
| Debt / equity as of 2026-09-03 | 3.84 | 1.29 | MCK lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.1% | +8.8% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | +10.4% | +13.4% | MCK higher |
| Dividend yield as of 2026-09-03 | +0.8% | +0.4% | COR higher |
| Dividend streak (yrs) SEC XBRL | 4 | 19 | MCK higher |
| Beta as of 2026-09-03 | -0.03 | 0.06 | |
| 1-year return as of 2026-10-08 close | +3.5% | +23.1% | MCK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.